

**Silicon Laboratories Inc.**  
**Condensed Consolidated Statements of Operations**  
(In thousands, except per share data)  
(Unaudited)

	<b>Three Months Ended</b>	
	<b>April 4, 2026</b>	<b>April 5, 2025</b>
Revenues	\$ 213,500	\$ 177,714
Cost of revenues	86,502	79,937
Gross profit	126,998	97,777
Operating expenses:		
Research and development	88,594	88,219
Selling, general and administrative	55,486	41,638
Operating expenses	144,080	129,857
Operating loss	(17,082)	(32,080)
Other income (expense):		
Interest income and other, net	3,626	3,793
Interest expense	(232)	(284)
Loss before income taxes	(13,688)	(28,571)
Provision for income taxes	2,209	1,899
Net loss	<u>\$ (15,897)</u>	<u>\$ (30,470)</u>
Loss per share:		
Basic	\$ (0.48)	\$ (0.94)
Diluted	\$ (0.48)	\$ (0.94)
Weighted-average common shares outstanding:		
Basic	32,963	32,465
Diluted	32,963	32,465

**Silicon Laboratories Inc.**  
**Condensed Consolidated Balance Sheets**  
(In thousands, except per share data)  
(Unaudited)

	<u>April 4, 2026</u>	<u>January 3, 2026</u>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 383,089	\$ 364,222
Short-term investments	55,767	79,400
Accounts receivable, net	77,120	64,513
Inventories	103,232	95,566
Prepaid expenses and other current assets	57,113	70,316
Total current assets	<u>676,321</u>	<u>674,017</u>
Property and equipment, net	131,821	128,643
Goodwill	376,389	376,389
Other intangible assets, net	20,836	23,130
Other assets, net	61,094	67,138
Total assets	<u>\$ 1,266,461</u>	<u>\$ 1,269,317</u>
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 56,384	\$ 50,717
Deferred revenue and returns liability	9,822	5,359
Other current liabilities	66,273	87,711
Total current liabilities	<u>132,479</u>	<u>143,787</u>
Other non-current liabilities	35,448	31,112
Total liabilities	<u>167,927</u>	<u>174,899</u>
Commitments and contingencies		
Stockholders' equity:		
Preferred stock – \$0.0001 par value; 10,000 shares authorized; no shares issued	—	—
Common stock – \$0.0001 par value; 250,000 shares authorized; 32,968 and 32,955 shares issued and outstanding at April 4, 2026 and January 3, 2026, respectively	3	3
Additional paid-in capital	177,551	157,402
Retained earnings	920,917	936,814
Accumulated other comprehensive income	63	199
Total stockholders' equity	<u>1,098,534</u>	<u>1,094,418</u>
Total liabilities and stockholders' equity	<u>\$ 1,266,461</u>	<u>\$ 1,269,317</u>

**Silicon Laboratories Inc.**  
**Condensed Consolidated Statements of Cash Flows**  
**(In thousands)**  
**(Unaudited)**

	<b>Three Months Ended</b>	
	<b>April 4, 2026</b>	<b>April 5, 2025</b>
<b>Operating Activities</b>		
Net loss	\$ (15,897)	\$ (30,470)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Depreciation of property and equipment	6,047	6,248
Amortization of other intangible assets	2,295	5,437
Stock-based compensation expense	21,055	19,714
Deferred income taxes	1,153	(1,514)
Changes in operating assets and liabilities:		
Accounts receivable	(12,608)	2,412
Inventories	(7,616)	22,098
Prepaid expenses and other assets	6,813	2,973
Accounts payable	3,387	9,234
Other current liabilities and income taxes	(7,415)	11,870
Deferred revenue and returns liability	4,463	3,405
Other non-current liabilities	3,257	(3,279)
Net cash provided by operating activities	<u>4,934</u>	<u>48,128</u>
<b>Investing Activities</b>		
Purchases of marketable securities	—	(19,728)
Sales of marketable securities	—	10,005
Maturities of marketable securities	23,461	10,675
Purchases of property and equipment	(9,837)	(4,852)
Proceeds from capital-related government incentives	1,265	—
Net cash provided by (used in) investing activities	<u>14,889</u>	<u>(3,900)</u>
<b>Financing Activities</b>		
Payment of taxes withheld for vested stock awards	(956)	(958)
Net cash used in financing activities	<u>(956)</u>	<u>(958)</u>
Increase in cash and cash equivalents	18,867	43,270
Cash and cash equivalents at beginning of period	364,222	281,607
Cash and cash equivalents at end of period	<u>\$ 383,089</u>	<u>\$ 324,877</u>

## Non-GAAP Financial Measurements

In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.

The non-GAAP financial measurements do not replace the presentation of Silicon Labs' GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs' financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.

### Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data)

Non-GAAP Income Statement Items	Three Months Ended April 4, 2026							
	GAAP Measure	GAAP Percent of Revenue	Stock Compensation Expense	Intangible Asset Amortization	Acquisition -Related Costs	Other Costs	Non- GAAP Measure	Non-GAAP Percent of Revenue
Revenues	\$ 213,500							
Gross profit	126,998	59.5 %	\$ 442	\$ —	\$ —	\$ —	\$ 127,440	59.7 %
Research and development	88,594	41.5 %	11,416	2,295	—	664	74,219	34.8 %
Selling, general and administrative	55,486	26.0 %	9,197	—	11,213	—	35,076	16.4 %
Operating expenses	144,080	67.5 %	20,613	2,295	11,213	664	109,295	51.2 %
Operating income (loss)	(17,082)	(8.0)%	21,055	2,295	11,213	664	18,145	8.5 %

Non-GAAP Earnings (Loss) Per Share and Income Tax Rate	Three Months Ended April 4, 2026								Non-GAAP Tax Percentage Rate
	GAAP Measure	GAAP Tax Percentage Rate	Stock Compensation Expense	Intangible Asset Amortization	Acquisition -Related Costs	Other Costs	Income Tax Adjustments	Non- GAAP Measure	
Income (loss) before income taxes	\$(13,688)		\$ 21,055	\$ 2,295	\$ 11,213	\$ 664	\$ —	\$ 21,539	
Provision for income taxes	2,209	(16.1)%					1,668	3,877	18.0 %
Net income (loss)	\$(15,897)							\$ 17,662	
			<b>Shares Excluded Due to Net Loss</b>						
Diluted shares outstanding	32,963			585				33,548	
Diluted earnings (loss) per share	\$ (0.48)							\$ 0.53	